https://orcid.org/0000-0002-2508-4031
References
- Brandt JT, Close SL, Iturria SJ, et al. (2007). Common polymorphisms of CYP2C19 and CYP2C9 affect the pharmacokinetic and pharmacodynamic response to clopidogrel but not prasugrel. J Thromb Haemost 5:2429–36.
- Jamei M, Marciniak S, Feng K, et al. (2009). The Simcyp population-based ADME simulator. Expert Opin Drug Metab Toxicol 5:211–23.
- Johnson TN, Boussery K, Rowland-Yeo K, et al. (2010). A semi-mechanistic model to predict the effects of liver cirrhosis on drug clearance. Clin Pharmacokinet 49:189–206.
- Ogawa SI, Shimizu M, Kamiya Y, et al. (2020a). Increased plasma concentrations of an antidyslipidemic drug pemafibrate co-administered with rifampicin or cyclosporine A in cynomolgus monkeys genotyped for the organic anion transporting polypeptide 1B1. Drug Metabol Pharmacokinet.doi:10.1016/j.dmpk.2020.03.005
- Ogawa SI, Shimizu M, Yamazaki H. (2020c). Plasma concentrations of pemafibrate with co-administered drugs predicted by physiologically based pharmacokinetic modeling in virtual populations with renal/hepatic impairment. Xenobiotica 50:1023–31.
- Ogawa SI, Tsunenari Y, Kawai H, Yamazaki H. (2019). Pharmacokinetics and metabolism of pemafibrate, a novel selective peroxisome proliferator-activated receptor-alpha modulator, in rats and monkeys. Biopharm Drug Dispos 40:12–7.
- Ogawa SI, Uehara S, Tsunenari Y, et al. (2020b). Prediction of circulating human metabolites of pemafibrate, a novel antidyslipidemic drug, using chimeric mice with humanized liver. Xenobiotica 50:769–75.
- Tornio A, Filppula AM, Niemi M, Backman JT. (2019). Clinical studies on drug–drug interactions involving metabolism and transport: methodology, pitfalls, and interpretation. Clin Pharmacol Ther 105:1345–61.
- Varma MVS, Bi YA, Lazzaro S, West M. (2019). Clopidogrel as a perpetrator of drug–drug interactions: a challenge for quantitative predictions? Clin Pharmacol Ther 105:1295–9.
- Varma MV, Kimoto E, Scialis R, et al. (2017). Transporter-mediated hepatic uptake plays an important role in the pharmacokinetics and drug–drug interactions of montelukast. Clin Pharmacol Ther 101:406–15.
- Yokote K, Yamashita S, Arai H, et al. (2019). Long-term efficacy and safety of pemafibrate, a novel selective peroxisome proliferator-activated receptor-alpha modulator (SPPARMalpha), in dyslipidemic patients with renal impairment. Int J Mol Sci 20:706.
- Yu J, Zhou Z, Tay-Sontheimer J, et al. (2018). Risk of clinically relevant pharmacokinetic-based drug–drug interactions with drugs approved by the U.S. Food and Drug Administration between 2013 and 2016. Drug Metab Dispos 46:835–45.